Kim Christopher
SEC insider (Form 3/4/5 filer). CIK 0002040022. Chairman and CMO at Apimeds Pharmaceuticals US, Inc. (APUS). 4 reported Form 4/5 transactions since Sep 2024; latest on Oct 15, 2025. Located in HOPEWELL, NJ.
Companies Kim Christopher has filed insider reports for
- Apimeds Pharmaceuticals US, Inc. (APUS): Director, Officer, Chairman and CMO
Kim Christopher
CIK: 0002040022
Transaction Breakdown
Open Market Buys (P)2 (50.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (50.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
APUS
Apimeds Pharmaceuticals US, Inc.
DirectorOfficer
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Oct 15, 2025APUS
Apimeds Pharmaceuticals US, Inc.
AwardDirectStock Option (right to buy)
3K shares- - May 16, 2025APUS
Apimeds Pharmaceuticals US, Inc.
AwardDirect250K shares- - May 14, 2025APUS
Apimeds Pharmaceuticals US, Inc.
PurchaseDirect7.7K shares at avg. $1.86$14K - May 13, 2025APUS
Apimeds Pharmaceuticals US, Inc.
PurchaseDirect19.8K shares at avg. $1.82$36K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 15, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | Award Stock Option (right to buy) | 3,000 | - | - | Direct |
| May 16, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | Award | 250,000 | - | - | Direct |
| May 14, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | Purchase | 7,730 | $1.86 | $14,378 | Direct |
| May 13, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | Purchase | 19,770 | $1.82 | $35,981 | Direct |
1-4 of 4 transactions